{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:13:29Z","timestamp":1793841209764,"version":"4.6.1"},"reference-count":44,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2017,5,4]],"date-time":"2017-05-04T00:00:00Z","timestamp":1493856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP\u2010341510"],"award-info":[{"award-number":["MOP\u2010341510"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Novel oral anticoagulants (NOACs) are alternatives to vitamin\u2010K antagonists (VKAs) for the prevention of thromboembolism. It is unclear how NOACs have been adopted in the UK since first introduced in 2008. The present study was conducted to describe the trends in the prescription of NOACs in the UK, including dabigatran, rivaroxaban and apixaban.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using the UK's Clinical Practice Research Datalink, the rates of new use of NOACs and VKAs from 2009 to 2015 were calculated using Poisson regression. Patient characteristics associated with NOAC initiation were identified using multivariate logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The overall rate of oral anticoagulant initiation increased by 58% over the study period [rate ratio (RR) 1.58; 95% confidence interval (CI) 1.23, 2.03], even as the rate of new VKA use decreased by 31% (RR 0.69; 95% CI 0.52, 0.93). By contrast, the rate of initiation of NOAC increased, particularly from 2012 onwards, with a 17\u2010fold increase from 2012 to 2015 (RR 17.68; 95% CI 12.16, 25.71). In 2015, NOACs accounted for 56.5% of oral anticoagulant prescriptions, with rivaroxaban prescribed most frequently, followed by apixaban and then dabigatran. Compared to VKAs, new NOAC users were less likely to have congestive heart failure, coronary artery disease and peripheral vascular disease, and more likely to have a history of ischaemic stroke.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the UK, the rate of initiation of NOACs has increased substantially since 2009, and these agents have now surpassed VKAs as the anticoagulant of choice. Moreover, the characteristics of patients initiated on NOACs have changed over time, and this should be accounted for in future studies comparing NOACs and VKAs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bcp.13299","type":"journal-article","created":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T20:42:44Z","timestamp":1491597764000},"page":"2096-2106","source":"Crossref","is-referenced-by-count":216,"title":["Trends in the prescription of novel oral anticoagulants in UK primary care"],"prefix":"10.1111","volume":"83","author":[{"given":"Simone Y.","family":"Loo","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Biostatistics, and Occupational Health McGill University  Montreal QC Canada"},{"name":"Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research Jewish General Hospital  Montreal QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Dell'Aniello","sequence":"additional","affiliation":[{"name":"Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research Jewish General Hospital  Montreal QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Huiart","sequence":"additional","affiliation":[{"name":"INSERM, CIC 1410 Centre Hospitalier Universitaire de la R\u00e9union  Saint\u2010Pierre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"Renoux","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Biostatistics, and Occupational Health McGill University  Montreal QC Canada"},{"name":"Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research Jewish General Hospital  Montreal QC Canada"},{"name":"Department of Neurology and Neurosurgery McGill University  Montreal QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,5,4]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv1037"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-12-200706190-00007"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035029"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.653048"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2013.07.009"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007903"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1302507"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0906598"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.853119"},{"key":"e_1_2_10_14_1","unstructured":"National Health Services: Lancashire Medicines Management Group(2013).Guidance for prescribing of dabigatran (Pradaxa) rivaroxaban (Xarelto) and apixaban (Eliquis) in patients with non\u2010valvular AF [online]. Available athttp:\/\/www.cumbria.nhs.uk\/ProfessionalZone\/MedicinesManagement\/Guidelines\/Prescribing\u2010Guidance\u2010for\u2010NOACs.pdf(last accessed 20 April 2016)."},{"key":"e_1_2_10_15_1","unstructured":"National Institute for Health and Clinical Excellence(2012).Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation. NICE technology appraisal guidance 256 [online]. Available athttps:\/\/www.nice.org.uk\/guidance\/ta256(last accessed 20 April 2016)."},{"key":"e_1_2_10_16_1","unstructured":"National Institute for Health and Clinical Excellence(2012).Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults. NICE technology appraisal guidance 157 [online]. Available athttps:\/\/www.nice.org.uk\/guidance\/ta157(last accessed 20 April 2016)."},{"key":"e_1_2_10_17_1","unstructured":"National Institute for Health and Clinical Excellence(2015).Apixaban for the treatment and secondary prevention of deep vein thrombosis and\/or pulmonary embolism. NICE technology appraisal guidance 341 [online]. Available athttps:\/\/www.nice.org.uk\/guidance\/ta341(last accessed 20 April 2016)."},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv098"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00701.x"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200427120-00004"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03537.x"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.23.5.686.32205"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp10X483562"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.22.2864"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-1584"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0134"},{"key":"e_1_2_10_27_1","unstructured":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9(2014).Les anticoagulants en France en 2014: \u00e9tat des lieux synth\u00e8se et surveillance. Available athttp:\/\/ansm.sante.fr\/var\/ansm_site\/storage\/original\/application\/26ed375830c56499badf0014eb3bb81b.pdf(last accessed 20 April 2016)."},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-016-1380-1"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.09.008"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.09.052"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-9560-6-6"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi825"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2014.05.013"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euu225"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D390"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2015.06.657"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep31477"},{"key":"e_1_2_10_38_1","unstructured":"National Health Services: East and North Hertfordshire Clinical Commissioning Group(2016).Guidelines for oral anticoagulation of patients with non\u2010valvular atrial fibrillation (AF) to prevent stroke[online]. Available athttp:\/\/www.enhertsccg.nhs.uk\/sites\/default\/files\/content_files\/Prescribing\/Local_Decisions\/Cardiovascular_system\/Anticoagulants\/Atrial%20Fibrillation%20Oral%20Anticoagulation%20Guidelines%20long%20v6%20ENHCCG.pdf(last accessed 20 April 2016)."},{"key":"e_1_2_10_39_1","unstructured":"National Health Services: Nottinghamshire Area Prescribing Committee(2016).Atrial fibrillation (non\u2010valvular): prescriber decision support on anticoagulation [online]. Available athttp:\/\/www.nottsapc.nhs.uk\/media\/1043\/anticoagulants\u2010in\u2010af.pdf(last accessed 20 April 2016)."},{"key":"e_1_2_10_40_1","unstructured":"National Health Services: Forth Valley(2014).Rivaroxaban as treatment for deep vein thrombosis and pulmonary embolism in adults [online]. Available athttp:\/\/www.carronbank.co.uk\/Clinical_Guidance\/rivaroxaban-in-dvt-pe.pdf(last accessed 20 April 2016)."},{"key":"e_1_2_10_41_1","unstructured":"National Health Services: Wiltshire Clinical Commissioning Group(2014).Direct oral anticoagulants (DOACs) for DVT and PE in adults. Available athttp:\/\/www.gwh.nhs.uk\/media\/236108\/doacs\u2010for\u2010dvt\u2010pe\u2010august\u20102016\u2010v\u20109.pdf(last accessed 20 April 2016)."},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2013.04.002"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2016.22.3.281"},{"issue":"21","key":"e_1_2_10_44_1","first-page":"A9664","article-title":"Utilization patterns of anticoagulants in non\u2010valvular atrial fibrillation after the entry of novel oral anticoagulants in the United States","volume":"126","author":"Hamilton M","year":"2016","journal-title":"Circulation"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht307.P543"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13299","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13299","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T05:23:19Z","timestamp":1696310599000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,4]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.1111\/bcp.13299"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13299","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,4]]}}}